Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 30th Preview)
-
In-vivo CAR-T dealmaking accelerates
Johnson & Johnson moved deeper into in vivo CAR-T with a new agreement covering Sail Biomedicines. J&J will pay $785 million upfront, including a $465 million equity investment, and may add up to $2.58 billion through an option to acquire the company, alongside up to $140 million in milestones. The collaboration targets immune-mediated diseases using Sail’s platform. Sail’s lead program, SAIL-0839, is designed to modulate CD4 and CD8 T cells for autoimmune indications. The companies’ strategy leans on Sail’s nanoparticle delivery and circular RNA design aimed at durable expression after short dosing cycles. J&J’s option structure signals confidence in the modality’s ability to reset immune pathways without ex vivo manufacturing constraints.
-
FDA advisory committee turns down Duchenne cell therapy
Capricor’s deramiocel was voted down by the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee in a contentious meeting. Panelists voted 9-3 against recommending approval for the Duchenne muscular dystrophy therapy after discussions centered on whether HOPE-3 trial evidence showed substantial effectiveness for cardiomyopathy endpoints. FDA reviewers and committee experts highlighted what they described as “very fragile” benefit signals, along with disagreements over statistical analysis-plan handling during the review cycle. Capricor’s CEO Linda Marbán challenged the agency’s framing, arguing the committee was pressured to consider draft statistical work not intended for the application. The decision stops short of a final FDA action, but it keeps deramiocel’s path uncertain as the company prepares for its ongoing second review posture.
-
Pfizer’s Phase 3 win for Litfulo expands autoimmune skin pipeline
Pfizer reported Phase 3 success for Litfulo (ritlecitinib) in active and stable nonsegmental vitiligo, delivering positive outcomes in two trials. The result reinforces Pfizer’s autoimmune dermatology strategy as it builds toward potential regulatory action and broader line extensions. The topline readout adds to a growing category of targeted oral therapies aimed at depigmenting diseases, where durability and consistent repigmentation have remained key challenges for drug development. Investors will now look for the detail level on response rates, durability, and subgroup outcomes as Pfizer prepares next steps across trial readouts and label strategy.
-
Adaptive Biotechnologies raises MRD outlook as ClonoSEQ testing grows
Adaptive Biotechnologies again lifted 2026 revenue guidance, citing continued expansion in its minimal residual disease (MRD) testing business. The company now expects 2026 MRD revenue of $268 million to $278 million, up from a prior range of $260 million to $270 million, driven by strong Q2 performance. Adaptive reported Q2 MRD revenue of $66.2 million, up 33% year over year, and delivered 36,111 ClonoSEQ tests in the quarter—43% higher than a year ago. CEO Chad Robins attributed growth to increased blood-based testing and continued uptake of MRD for serial monitoring rather than only one-time assessments. The update underscores the commercialization momentum for MRD platforms, even as immune medicine revenue declined year over year.
-
AI cellular foundation models get major GSK funding
Relation Therapeutics secured an expanded research collaboration with GSK worth up to $110 million to generate large-scale cellular perturbation datasets for cellular foundation models. Under the pact, Relation will use automated laboratories to generate petascale, time-resolved, multi-omic readouts intended to improve target discovery confidence. Relation simultaneously unveiled MORGAN (Multi-Omic Regulatory Genomics using Artificial Neural Networks), positioning it as a general-purpose cellular model that can predict how cells respond to genetic and pharmacological interventions across disease contexts. The collaboration did not name initial disease areas. For biopharma, the deal signals a push toward model training on standardized, high-consistency perturbation data intended to reduce variability issues that have hampered translational confidence.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.